Retatrutide is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Retatrutide (development code: LY3437943) is a synthetic 36-amino acid polypeptide functioning as a triple incretin receptor agonist — simultaneously targeting GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GcgR (glucagon receptor). As a GGG triple agonist, retatrutide extends beyond dual agonists such as tirzepatide by adding glucagon receptor activity, which is investigated for its potential contribution to enhanced fat oxidation and thermogenesis.
Published Phase 2 clinical data in the New England Journal of Medicine (2023) reported mean bodyweight reductions of 17.5% to 24.2% over 48 weeks across dose groups in participants with obesity — substantially exceeding published outcomes for semaglutide and tirzepatide at comparable timepoints. Retatrutide is currently in Phase 3 clinical trials (NCT05929066) for obesity and type 2 diabetes, and has generated research interest in MASH/NAFLD (fatty liver) and cardiovascular risk reduction.
PeptidesFromChina.co supplies retatrutide as a lyophilized powder, synthesized to 99%+ purity verified by HPLC and Mass Spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. Retatrutide is an investigational compound — all supply is for laboratory research use only and is not for human consumption.
| Chemical Class | Synthetic polypeptide, triple incretin agonist (GGG agonist) |
|---|---|
| Synonyms | LY3437943 |
| Mechanism | GLP-1R / GIPR / GcgR triple agonist |
| Amino Acids | 36 |
| Molecular Weight | ~4697 Da (free base) |
| CAS Number | 2381272-17-7 |
| Clinical Status | Phase 3 (NCT05929066, as of 2024) |
| Research Areas | Obesity, metabolic syndrome, type 2 diabetes, MASH/NAFLD, cardiovascular risk markers, thermogenesis |
| Form | Lyophilized powder |
| Storage | −20°C, protect from light and moisture |
| Molecular Formula | N/A — acylated 39-aa peptide |
| Sequence | Available on request (39 aa, C18 fatty acid acylation via linker) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Retatrutide | 5 mg | 10 vials | ≥98% | In Stock | $72.00 |
| Retatrutide | 10 mg | 10 vials | ≥98% | In Stock | $110.00 |
| Retatrutide | 15 mg | 10 vials | ≥98% | In Stock | $132.00 |
| Retatrutide | 20 mg | 10 vials | ≥98% | In Stock | $145.00 |
| Retatrutide | 30 mg | 10 vials | ≥98% | In Stock | $200.00 |
| Retatrutide | 40 mg | 10 vials | ≥98% | In Stock | $263.00 |
| Retatrutide | 50 mg | 10 vials | ≥98% | In Stock | $325.00 |
| Retatrutide | 60 mg | 10 vials | ≥98% | In Stock | $375.00 |
Testing method: HPLC / LC-MS (["HPLC","LC-MS","Endotoxins","Sterility","Water Content","Assay","Microbiology"]). Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Available documentation: Manufacturer COA · Simple COA. Where provided, these documents reflect the manufacturer's batch testing for this compound.
Phase 2 clinical research data on retatrutide demonstrated dose-dependent bodyweight reductions exceeding those reported for tirzepatide and semaglutide at comparable time points. The addition of glucagon receptor agonism to dual GLP-1/GIP activity is investigated for additive fat oxidation and thermogenesis effects — mechanisms being studied in the context of severe obesity and metabolic disease.
As a GLP-1R agonist, retatrutide carries glucose-lowering activity through incretin-mediated insulin secretion and glucagon suppression. Phase 2 published data showed meaningful HbA1c reductions alongside substantial bodyweight effects in participants with type 2 diabetes, establishing it as a subject of interest in multi-factorial metabolic disease research.
Emerging research interest follows the cardiovascular outcome data from related GLP-1 class compounds and early signals from retatrutide's Phase 2 data regarding liver fat reduction in MASH/NAFLD models. Cardiovascular risk marker changes observed in Phase 2 are being monitored in the ongoing Phase 3 program as secondary endpoints.
Semaglutide is a GLP-1R mono-agonist. Tirzepatide adds GIP receptor activity (dual agonist). Retatrutide adds glucagon receptor agonism, making it a triple agonist (GGG agonist). Published Phase 2 data suggests greater weight reduction with retatrutide vs. both at comparable timepoints.
As of 2024, retatrutide is in Phase 3 clinical trials (NCT05929066) for obesity and type 2 diabetes, conducted by Eli Lilly and Company.
99%+ purity verified by HPLC and Mass Spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control.
Lyophilized retatrutide should be stored at −20°C, protected from light and moisture.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.